PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported fourth-quarter and full-year 2025 financial results while providing updates on its clinical program studying PBFT02, a gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results